Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Link Between Sexual Orientation and Cancer

May 12, 2011
By Anna Azvolinsky
Publication
Article
OncologyONCOLOGY Vol 25 No 7
Volume 25
Issue 7

A study published in the journal Cancer on May 9 has now specifically examined the outcome of cancer survivorship of the gay, lesbian, and bisexual population. The study authors found that cancer outcomes differ based on sexual orientation.

While populations are often analyzed by age, sex, and race with respect to cancer risk and cancer outcomes, sexual orientation has previously not been studied as a factor for either cancer incidence or cancer outcome. A study published in the journal Cancer on May 9, 2011 has now specifically examined the cancer survivorship of the gay, lesbian, and bisexual population (DOI: 10.1002/cncr.25950). The study authors found that cancer outcomes differ based on sexual orientation.

While there is a dearth of data on cancer survivorship among gay/lesbian/bisexual populations, it has been suggested that these populations generally engage in behaviors that are associated with greater cancer risk. These risk factors include a higher incidence of obesity and alcohol consumption among the lesbian population and a higher rate of smoking among gay men, lesbians, and bisexuals. Furthermore, recent studies have shown that same-sex sexual contact is linked to a higher incidence of head and neck and anal cancers. However, the question of cancer survivorship with respect to sexual orientation has not been well-studied, since most cancer surveillance studies do not record this statistic.

Methods and results

Ulrike Boehmer, PhD and her colleagues from Boston University used pooled data from the California Health interview survey from 2001, 2003, and 2005 to examine cancer prevalence among men and women by sexual orientation. Additionally, the authors used self-reported health surveys to analyze cancer survivorship based on sexual orientation. The data included data from 3,690 men and 7,252 women who had reported a cancer diagnosis as adults. This is the largest state health survey executed in the United States.

The study found a significant difference in cancer outcomes among heterosexual men compared with homosexual men. Homosexual men were found to be 1.9 times more likely to self-report a cancer diagnosis than were heterosexual men. No differences in cancer survivorship were found between the two groups. Homosexual men reported a significantly lower frequency of prostate cancer-one-third the frequency of other men. Homosexual and bisexual men had a greater incidence of all other cancers.

Although homosexual women did not have a higher incidence of cancer, these women did report lower overall health as cancer survivors compared to heterosexual women. Unilke the male population, which did not differ in self-reported health based on sexual orientation, lesbian cancer survivors were 2.0 times and bisexual women survivors were 2.3 times more likely to report poor or fair health compared with their heterosexual cancer survivor counterparts.

The study found that bisexual women had a two-fold higher prevalence of cervical cancer compared with other women. Uterine cancer was most prevalent among homosexual women, and the incidence of all other cancers was higher among heterosexual women.

Follow up questions and implications

Follow-up studies should be prospective in nature in order to address self-reporting bias. Additionally, future studies should be expanded geographically to include cancer survivors from across the United States and should not rely on self-reporting data.

Many questions should be addressed in the extension of this research. Whether homosexual men are reporting more cancer survivorship compared with heterosexual men because more have been diagnosed with cancer or because more are surviving their diagnosis is unclear from this study. The frequency of cancer diagnoses among heterosexual women compared to homosexual women is also unclear.

This study has implications for US cancer control efforts, including disease management and prevention of secondary cancers by the Centers for Disease Control and Prevention as well as the National Cancer Institute and the American Cancer Society. Approximately 4% of the US population are cancer survivors, and knowing who is included in this population, as the authors point out, is important for providing survivorship care, including psychosocial and medical care. Knowing the make-up of the cancer survivorship population can only aid public health and healthcare agencies in providing for specific needs of subsets of this population, including lesbian, gay, and bisexual survivors.

The first author of the study highlighted that the higher incidence of cancers among gay men found in the study should stimulate planning and execution for better screening, education, and primary prevention among this population by public health agencies. “Because more gay men report as cancer survivors, we need foremost programs for gay men that focus on primary cancer prevention and early cancer detection. Because more lesbian and bisexual women than heterosexual women with cancer report that they are in poor health, we need foremost programs and services that improve the well-being of lesbian and bisexual cancer survivors,” said Dr. Boehmer.

Articles in this issue

Who Knows How to Treat Systemic Light Chain Amyloidosis?
Uniform Risk-Stratification and Response Criteria Are Paving the Way to Evidence-Based Treatment of AL Amyloidosis
Proton Therapy for Prostate Cancer: Show Me the CER!
Back to the Future: a Proton Pro/Con
Proton Therapy for Prostate Cancer
Treatment of Immunoglobulin Light Chain (Primary or AL) Amyloidosis
ALK-Targeted Therapy for Lung Cancer: Ready for Prime Time
Management of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
Multiple Myeloma Precursor Disease: Current Clinical and Epidemiological Insights and Future Opportunities
MGUS and Smoldering Myeloma: the Most Prevalent of Plasma Cell Dyscrasias
ALK-Targeted Therapy in NSCLC: Likely to Be of Benefit but Not Quite Ready for Prime Time
The Future of NSCLC: Molecular Profiles Guiding Treatment Decisions
A Care Model for the Future: the Oncology Medical Home
A Care Model for the Future: the Oncology Medical Home
Aloe Vera (Aloe barbadensis, Aloe capensis)
Aloe Vera (Aloe barbadensis, Aloe capensis)
Standardizing Patient Education for Safe Handling of Chemotherapy at Home
Recent Videos
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Related Content
Advertisement

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.


1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
April 15th 2025
Podcast

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.


Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC

Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC

Ariana Pelosci
June 2nd 2025
Article

SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.


42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article
Related Content
Advertisement

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.


1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
April 15th 2025
Podcast

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.


Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC

Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC

Ariana Pelosci
June 2nd 2025
Article

SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.


42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.